Chronic myeloid leukemia (CML) in Asia has an incidence rather lower than in Western
countries yet tends to afflict a younger population. As in the West, imatinib mesylate (IM …

BACKGROUND: The annual incidence of chronic myeloid leukemia (CML) in the United
States is approximately 4800 cases. With the success of tyrosine kinase inhibitor (TKI) …

Background In the last decade, the use of imatinib has brought a paradigm shift in the
management of chronic myeloid leukemia (CML). In India, imatinib has been available for …

Purpose Imatinib mesylate is used as first line therapy in the treatment of chronic myeloid
leukaemia. This study was designed to study the correlation of plasma levels of imatinib with …

Chronic myeloid leukemia patients with different BCR-ABL transcripts might respond
differently to Imatinib mesylate. This prompted us to study BCR-ABL transcripts in chronic …

Objectives: A study to determine the clinical, hematological, cytogenetic, and molecular
profile in chronic myeloid leukemia (CML) patient in and around Eastern UP, India. Materials …

Chronic myeloid leukemia (CML) management varies across Asia due to disparities in
affluence and healthcare provision. We surveyed CML management practice at 33 hospitals …

Purpose of Review A large number of chronic myeloid leukemia (CML) patients receiving
tyrosine kinase inhibitors (TKIs) can now enjoy a deep molecular control of the disease and …

CYP3A5 is a member of the CYP3A gene family which metabolizes 50% of therapeutic
drugs and steroid hormones. CYP3A5* 3 and CYP3A5* 6 polymorphisms exhibit inter …

For a select number of drugs, proper management of patients includes monitoring serum or
plasma concentrations of the drugs and adjusting the doses accordingly–this practice is …